The company is increasing its awareness campaign for cancer advocacy, including a partnership with the Chicago Cubs announced ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Radium-223 in mCRPC showed long-term favorable safety, low second primary malignancies/fracture rates, and consistent overall ...

Todd Weiser – who recently performed White Plains Hospital’s first ION-assisted bronchoscopy – describes the ION Robotic Bronchoscopy Platform as ...

NANTES, France – June 2, 2025, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided clinical updates on Tedopi®, the “off-the-shelf” neo-epitope-based therapeutic ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

This five-year analysis of the C-144-01 trial represents unprecedented durability and duration of follow-up in advanced melanoma patients previously treated with anti-PD-1 and targeted therapy, where ...

Amgen today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

The new consortium aims to bolster the five-year survival rate of high-risk pancreatic cancer patients from 10% to 30% by ...

Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...

MONDAY, June 2, 2025 (HealthDay News) — Wildfire smoke could make it harder for people with lung cancer to survive, a new ...